Naltrexone during pregnancy being considered due to prenatal opioid exposure

The federal government is considering balancing the risks of naltrexone administered during pregnancy with the risks of neonatal abstinence syndrome (NAS). The Substance Abuse and Mental Health Services Administration (SAMHSA) has released a draft of its report to Congress on prenatal opioid exposure and NAS. The draft was published in the Jan. 19 Federal Register, and was open for public comment until Feb. 21.
Source: The Brown University Child and Adolescent Psychopharmacology Update - Category: Psychiatry Tags: Substance Use Disorders Source Type: research